Flyer
AI Drug Discovery & Development Solution
AI Drug Discovery & Development
Solution
Solving the AIDD validation bottleneck,
Closing the gap to pre-clinical development
From AI Design to IND Readiness
Test Faster.
Identify True Functional
Hits Early
From Candidate Selection
to IND Readiness
Advance Better Candidates.
Generate more value from every
Validate functionality, developability,
and biological relevance to confidently
select the candidates most likely
to succeed.
Accelerate Preclinical Candidate(PCC)
selection, reduce CMC risk, and move
promising candidates to IND faster.
Al-designed sequence
through integrated wet-lab
validation and Al-ready data.
Proven Expertise
in Antibody
20+
20+
2350+
Years of Deep
Projects in
Projects in the Clinical
Phase and Marketed
Expertise in Biologics
Discovery
Therapeutic Antibody
Therapeutics
by Jun. 2026
Prove
Select
Optimize
Advance
Wet-Lab functional
sample prep & CMC
developability service
IND-enabling CMC service
validation service
Screen
Validate
Advance
AI Drug Discovery
The path between AI design and therapeutic reality
Integrated Platform
Expression to PK/Tox, all in one workflow
Seamless program progression
Zero handoff friction, faster decisions
Antibody Design and
107-8
1
Generation
Fast & High-Throughput
10-day turnaround from gene to data
Automated high-throughput screening
Hundreds of samples processed daily
105-6
Learn
Primary Screening
2
Comprehensive Screening Strategy
102-3
HTP Screening
3
Balancing Functionality and Developability
Established assays and animal models
In Vitro
101-2
4
Bioassay
AI-Ready Data
Customized, AI-ready data outputs
Flexible reporting formats
In Vivo
1-5
5
Study
Optimized for model training
ProBioCDMO.com
+1-732-885-9188
Accelerating Ideas. Delivering Impact.
Comprehensive Screening Strategy
HTP Functional Assay
Micro-developability
Cell-based Functional Assay
Animal Study
Reporter gene assay
Affinity binding
Thermal stability (DSF/DLS)
PD
ADCC/TDCC/CDC
Internalization assay
Affinity ranking
Charge variants (iclEF)
PK
Non-specific Binding
(BVP/DNA/LPS/Insulin ELISA)
Reporter gene assay
Tox
Immunogenicity assessment
Customized assay
Self-interaction (AC-SINS)
Mouse/rat/canine/
feline /cyno
4 Months From AI sequence to Pre-Tox Study
Timeline (Month)
1
2
3
4
5
HTP antibody expression (10-20ml)
HTP primary screen (Functional & Micro-Developability)
MOA-based functional assays
Scale-up Production (1L)
In vivo efficacy study
PK and Pre-Tox study in NHP
AI Drug Development
From transfection to Tox DS ready in as fast as 4.5 months
PrepCMC Fast
PrepCMC
ExpressCMC with
PrepCMC
Sample Preparation
Developability Study
Uses the same host cell line
and vector system as formal
CMC
Advance process development
earlier than conventional
timelines
Select the optimal CMC
candidate using representative
materials
Generates representative
materials aligned with CMC
specifications
Identify development risks
and key process parameters
early
Deliver Tox-ready drug
substance in as little as 4.5
months from transfection
Ensures consistency in critical
quality attributes (CQAs)
De-risk and accelerate formal
CMC development
Enables rapid progression
for complex molecules and
high-concentration formu
lations